DMD and Duchenne muscular dystrophy: Intramuscularly delivered CjCas9 and an sgRNA targeting the mutant exon 23 are sufficient to restore dystrophin expression and increase skeletal muscle force in the DMD mice with a 1-bp insertion or 14-bp deletion in exon 23 [137].